Experience with interferon-gamma in the therapy of sexually transmitted viral infections
Objective. To investigate the efficacy and safety of Ingaron (interferon-gamma) in the combined therapy of sexually transmitted viral infections (STVIs).Rakhmatulina M.R., Bolshenko N.V.
Subjects and methods. The investigation included 26 patients diagnosed with anogenital herpetic infection (Subgroups 1A and 1B) and 64 patients with anogenital (venereal) warts (Subgroups 2A, 2B, 2C, and 2D). Subgroup 1A received combined therapy with acyclovir and Ingaron; Subgroup 1B took acyclovir only; Subgroup 2A had Ingaron in combination with cryodestruction; Subgroup 2B received cryodestruction; and Subgroup 2C took Ingaron in combination with destruction with Solcoderm; Subgroup 2D had destruction with Solcoderm.
Results. Recurrent anogenital herpetic infection was absent in 92.9% of the patients receiving combined therapy with acyclovir and Ingaron and in 58.3% of those on acyclovir therapy. In patients with anogenital warts, the efficiency of combined therapy (Ingaron + cryodestruction; Ingaron + Solcoderm) exceeded that of therapy with cryodestruction only or with Solcoderm: 94.1, 93.3, 58.8, and 40.0%, respectively. During therapy, there were no serious adverse events or clinically significant changes in the general clinical and biochemical blood tests.
Conclusion. The use of Ingaron in the combined therapy of viral STVIs demonstrates a high clinical efficacy and safety profile and assists in reducing the rate of recurrence.
Keywords
papillomavirus infection
anogenital warts
genital herpes
interferons
Ingaron
interferon-gamma
References
1. Глобальная стратегия сектора здравоохранения по инфекциям, передаваемым половым путем 2016-2021 гг. ВОЗ; 2016. Available at: http://www.who.int/mediacentre/factsheets/fs110/ru/ [The global health sector strategy for infections transmitted sexually transmitted 2016-2021. WHO; 2016. Available at: http://www.who.int/mediacentre/factsheets/fs110/ru/]
2. European guidelines for the management of genital herpes. 2017. Available at: https://www.iusti.org/regions/Europe/pdf/2017/2017EuropeanGuidelineForManagementOfGenitalHerpes061216.pdf
3. Роговская С.А., Акопова Е.С., Коган Е.А. Совершенствование лечебно-диагностических подходов к ВПЧ-инфекции гениталий. Медицинский альманах. 2012; 5: 85-7. [Rogovskaya S.A., Akopova E.S., Kogan E.A. Improvement of treatment and diagnostic approaches to HPV infection of the genitals. Prakticheskaya medicina, 2012; 9 (65): 236-240. (in Russian)].
4. Рахматулина М.Р., Большенко Н.В., Куевда Д.А. Особенности клинического течения папилломавирусной инфекции в зависимости от генотипа и количественных показателей вирусов папилломы человека высокого онкогенного риска. Вестник дерматологии и венерологии. 2014; 3: 95-105. [Rahmatulina M.R., Bol’shenko N.V., Kuevda D.A.. Particular features of the clinical course of the papilloma viral infection depending on quantitative indices of human papilloma viruses of a high carcinogenic risk. Vestnik dermatologii i venerologii, 2014; 3: 95-105. (in Russian)].
5. Handfield C., Kwock J., MacLeod A.S. Innate antiviral immunity in the skin. Trends Immunol. 2018; 39(4): 328-40.
6. Shcheglovitova O.N., Boldyreva N.V., Sklyankina N.N., Babayants A.A., Frolova I.S. IFN-α, IFN-β, and IFN-γ have different effect on the production of proinflammatory factors deposited in weibel-palade bodies of endothelial cells infected with herpes simplex virus type 1. Bull. Exp. Biol. Med. 2016; 161(2): 270-5.
7. do Carmo Vasconcelos de Carvalho V., de Macêdo J.L., de Lima C.A., da Conceição Gomes de Lima M., de Andrade Heráclio S., Amorim M. et al. IFN-gamma and IL-12B polymorphisms in women with cervical intraepithellial neoplasia caused by human papillomavirus. Mol. Biol. Rep. 2012; 39(7): 7627-34.
8. Merheb R., Abdel-Massih R.M., Karam M.C. Immunomodulatory effect of natural and modified Citrus pectin on cytokine levels in the spleen of BALB/c mice. Int. J. Biol. Macromol. 2018; 121: 1-5.
9. Póvoa T.F., Oliveira E.R.A., Basílio-de-Oliveira C.A. Correction: peripheral organs of dengue fatal cases present strong pro-inflammatory response with participation of IFN-Gamma-, TNF-Alpha- and RANTES-producing cells. PLoS One. 2018; 13(3): e0195140.
Received 19.11.2018
Accepted 07.12.2018
About the Authors
Rakhmatulina, Margarita R., MD, professor of the Department a dermatovenereology and cosmetology with a course of clinical laboratory diagnostics, State Research Center-Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency.123098, Russia, Moscow, Zhivopisnaya str., 46. Tel.: +79162031003. E-mail: ra.marg@yandex.ru
Bolshenko, Natalia V., PhD, the head researcher of Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance.
111123, Russia, Moscow, Novogireevskaya str. 3a. The chief of the consultative-diagnostic department Moscow Regional Clinical Dermatovenerological Center, Moscow, Russia. 111123, Russia, Moscow, Schepkina str. 61/2, building 2. Tel.: +79164224280. E-mail: sanabol@mail.ru
For citations: Rakhmatulina M.R., Bolshenko N.V. Experience with interferon-gamma in the therapy of sexually transmitted viral infections. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (12): 149-56. (in Russian)
http://dx.doi.org/10.18565/aig.2018.12.149-156
Similar Articles
